BioCryst Pharmaceuticals Files 8-K Report
Ticker: BCRX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 882796
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: BCRX
TL;DR
BioCryst filed an 8-K, no major news yet, keep watching.
AI Summary
On January 13, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of events and does not disclose specific material events or financial updates in this particular document.
Why It Matters
This filing indicates that BioCryst Pharmaceuticals, Inc. is adhering to regulatory reporting requirements by submitting an 8-K. Investors should monitor future filings for specific material events.
Risk Assessment
Risk Level: low — The filing is a routine procedural document and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 62-1413174 (identifier) — IRS Number
- 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 (address) — Principal Executive Offices
- (919) 859-1302 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing for BioCryst Pharmaceuticals, Inc.?
This 8-K filing serves as a Current Report, indicating that BioCryst Pharmaceuticals, Inc. is reporting on events as required by Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is January 13, 2025.
Where are BioCryst Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices of BioCryst Pharmaceuticals, Inc. are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is BioCryst Pharmaceuticals, Inc.'s telephone number?
BioCryst Pharmaceuticals, Inc.'s telephone number, including area code, is (919) 859-1302.
In which state was BioCryst Pharmaceuticals, Inc. incorporated?
BioCryst Pharmaceuticals, Inc. was incorporated in Delaware.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-01-13 07:09:33
Filing Documents
- f8k_011325.htm (8-K) — 22KB
- 0001171843-25-000190.txt ( ) — 190KB
- bcrx-20250113.xsd (EX-101.SCH) — 3KB
- bcrx-20250113_lab.xml (EX-101.LAB) — 33KB
- bcrx-20250113_pre.xml (EX-101.PRE) — 22KB
- f8k_011325_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. As previously announced, BioCryst Pharmaceuticals, Inc. (the "Company") will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 6:00 p.m. ET. The slides prepared in connection with this upcoming webcast presentation, which include information relating to our drug discovery and development programs, will be posted on Monday, January 13, 2025, in the Events & Presentations section of the Company's Investor Relations website at https://ir.biocryst.com/news-events/events. The Company routinely posts important information, including news releases, announcements and other statements about its business and results of operations, that may be deemed material to investors on the Company's Investors Relations website at https://ir.biocryst.com/news-events/press-releases. The Company uses its website as a means of disclosing material, nonpublic information and for complying with the Company's disclosure obligations under Regulation FD. Investors should monitor the Company's Investor Relations website in addition to following the Company's press releases, filings with the SEC, public conference calls and webcasts. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 BioCryst Pharmaceuticals, Inc. By: /s/ Alane Barnes Alane Barnes Chief Legal Officer